Ra Pharmaceuticals

December 18, 2018

Achillion’s first oral Soliris rival hits the buffers

Achillion’s pivot to a next-gen project in paroxysmal nocturnal haemoglobinuria is an admission that its first attempt to compete with Alexion’s Soliris has fallen short.

December 14, 2018

Upcoming events – Verona waits to exhale and a new test for Alexion

Verona Pharma needs another COPD win, while Alexion seeks a new use for its Soliris successor.

December 12, 2018

Ra joins the challenge to Alexion’s Soliris stranglehold

Promising data in myasthenia gravis, plus a pledge to compete on price, means that Ra Pharmaceuticals’ zilucoplan could soon give Alexion a headache – and others are…

March 15, 2018

Alexion and the cash cow that never runs out of milk

December 08, 2017

Snippet roundup: drug spending growth shrinks but M&A holds up in medtech

June 28, 2017

Unshakeable Alexion sees off Ra and Akari

May 24, 2017

More Alexion turbulence could flush out a buyer

January 24, 2017

Ra Pharmaceuticals

Achillion’s first oral Soliris rival hits the buffers

Upcoming events – Verona waits to exhale and a new test for Alexion

Ra joins the challenge to Alexion’s Soliris stranglehold

Alexion and the cash cow that never runs out of milk

Snippet roundup: drug spending growth shrinks but M&A holds up in medtech

Unshakeable Alexion sees off Ra and Akari

More Alexion turbulence could flush out a buyer

Investors in new issues embrace 2016’s new reality

Latest Reports

Vantage Pharma, Biotech and Medtech 2018 in Review

Vantage 2019 Preview

Editor's Picks

Array-size deals don’t come around too often

Takeda casts doubt on the remaining approach to amyloidosis

EHA 2019 – Global Blood faces sickle cell questions

Liquid biopsies: the future of cancer diagnosis?

Time to restock big pharma’s leaking pipeline